Sanofi Drug Shows Long-Term Benefit in Rare Disease

Indolent systemic mastocytosis is a rare, chronic disease caused by an abnormal accumulation of mast cells, with a prevalence estimated to be between 1 in 7,700 and 1 in 10,400 people in Europe. The disease is driven by a mutation in the KIT gene, most commonly the KIT D816V mutation, in approximately 95% of cases. AYVAKIT is a tyrosine kinase inhibitor that potently and selectively targets this specific mutation, inhibiting the abnormal mast cell proliferation and activation that cause symptoms. The PIONEER trial is a three-part Phase 2 study that began in April 2019 to evaluate the efficacy and safety of avapritinib in patients with indolent systemic mastocytosis. Part one of the study focused on dose-finding, part two was the registration-enabling portion comparing the drug to a placebo, and part three is a long-term open-label extension for all participants. The trial's primary endpoint for registration was the mean change in the total symptom score as reported by patients. The U.S. Food and Drug Administration (FDA) first approved Ayvakit for adults with advanced systemic mastocytosis in June 2021, and this was followed by an approval for indolent systemic mastocytosis in May 2023. The drug is also approved for certain patients with gastrointestinal stromal tumors (GIST). The presentation of these long-term results comes after Sanofi's acquisition of Blueprint Medicines, which was announced in June 2025 and finalized in July 2025. This acquisition, valued at approximately $9.1 billion, was a strategic move by Sanofi to bolster its immunology portfolio, with Ayvakit being a key commercialized asset in the deal. The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting is a major event for specialists in the field, making it a significant platform for sharing long-term data on new therapies for rare immunological diseases. The 2026 meeting is expected to draw thousands of allergists, immunologists, and researchers.